Biopsin Pte. Ltd.

Biopsin Pte. Ltd. is a Singapore-based company focused on developing innovative diagnostic tools that enhance disease detection and management, primarily through advanced biomarker assays and diagnostic kits. Founded in 2018, Biopsin Pte.

Ltd. operates from Singapore and is dedicated to creating diagnostic solutions for healthcare. The company raised USD 480,000 in Seed funding on May 31, 2022, with key investors including SOSV, Dorf Ketal Chemicals Pte. Ltd.

, and Entrepreneur First. The company has successfully completed a single funding round and currently has a valuation of USD 2. 672 mn. The CEO and co-founder, Amit Kumar, has a background in healthcare technology.

Biopsin specializes in developing innovative diagnostic tools aimed at enhancing disease detection and management. Their core product offerings include advanced biomarker assays and diagnostic kits designed for use in clinical laboratories and healthcare settings. These products leverage proprietary technologies to analyze biological samples, providing healthcare professionals with critical insights into patient conditions, thereby aiding in timely interventions. The primary end users of Biopsin’s products comprise hospitals, diagnostic laboratories, and research institutions, who utilize these assays to diagnose various diseases, including cancer and autoimmune disorders.

Biopsin has strategically positioned its products in markets such as North America, Europe, and parts of Asia, ensuring broad accessibility to healthcare providers in these regions. Biopsin generates revenue primarily through direct sales of its diagnostic products and strategic partnerships with healthcare providers and laboratories. The company’s transaction structure typically involves B2B relationships, where clients purchase diagnostic kits on a contract basis, allowing for a consistent supply to meet demand within clinical settings. Pricing plans for these products are crafted to accommodate the diverse needs of their client base, which may include bulk purchase agreements for larger healthcare institutions.

Biopsin's flagship products are integral to the diagnostic workflows in laboratories, further solidifying the company’s role as a key player in the medical diagnostics industry. This model fosters a steady revenue stream while promoting long-term partnerships within the healthcare ecosystem. Biopsin Pte. Ltd.

plans to leverage its recent Seed funding of USD 480,000 to enhance its product offerings and expand into new markets. The company is focused on developing additional diagnostic tools aimed at improving disease management, with plans for new product launches expected in the near future. Furthermore, Biopsin aims to target expansion into emerging markets in Asia and Europe by 2024, ensuring a broader reach for its innovative solutions.